{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:59:43Z","timestamp":1773327583279,"version":"3.50.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We characterised early changes in laboratory parameters in Japanese patients with rheumatoid arthritis and assessed whether these changes at Month (M)1 were predictive of tofacitinib efficacy at M3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis included pooled data from Japanese patients receiving tofacitinib or placebo in three Phase 2\/Phase 3 studies (NCT00603512; NCT00687193; NCT00847613). Outcomes included changes from baseline in laboratory parameters (Week 2 and M1\/3); efficacy end points were Disease Activity Score in 28 joints, based on C-reactive protein; Disease Activity Score in 28 joints, based on erythrocyte sedimentation rate; and American College of Rheumatology-N index at M3. Univariate\/multivariable analyses assessed whether changes at M1 were predictive of efficacy at M3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 467 patients receiving tofacitinib and 104 receiving placebo were included. Tofacitinib treatment was associated with decreases from baseline in C-reactive protein, erythrocyte sedimentation rate, neutrophils, and platelets and increases in lymphocytes, haemoglobin, and lipids up to M3. Decreased platelet count and increased low-density lipoprotein cholesterol and haemoglobin at M1 were predictive of changes in efficacy outcomes at M3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Changes in laboratory parameters at M1 could potentially be used to assess whether tofacitinib therapy will be effective at M3; however, further investigation is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae109","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:36:55Z","timestamp":1733877415000},"page":"417-424","source":"Crossref","is-referenced-by-count":2,"title":["Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2\/3 randomised controlled clinical trials"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu, Fukuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Sanno Medical Center , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Toyoizumi","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan G.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9569-6834","authenticated-orcid":false,"given":"Tomohiro","family":"Hirose","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University , Tokyo,","place":["Japan"]},{"name":"Department of Rheumatology and Applied Immunology, Saitama Medical University , Iruma, Saitama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025050812114049700_R1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025050812114049700_R2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025050812114049700_R3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025050812114049700_R4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025050812114049700_R5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025050812114049700_R6","first-page":"2177","article-title":"Association of anemia and physical disability among patients with rheumatoid arthritis","volume":"34","author":"Han","year":"2007","journal-title":"J Rheumatol"},{"key":"2025050812114049700_R7","volume-title":"StatPearls [Internet]","author":"Chauhan","year":"2024"},{"key":"2025050812114049700_R8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000739","article-title":"Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome","volume":"4","author":"Fragoulis","year":"2018","journal-title":"RMD Open"},{"key":"2025050812114049700_R9","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3899\/jrheum.090639","article-title":"Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis","volume":"37","author":"Chung","year":"2010","journal-title":"J Rheumatol"},{"key":"2025050812114049700_R10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, iorra: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025050812114049700_R11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755844","article-title":"Toward overcoming treatment failure in rheumatoid arthritis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2025050812114049700_R12","doi-asserted-by":"crossref","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review","volume":"11","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025050812114049700_R13","article-title":"XELJANZ\u00ae (Tofacitinib): Summary of Product Characteristics","author":"European Medicines Agency","year":"2022"},{"key":"2025050812114049700_R14","article-title":"XELJANZ\u00ae (Tofacitinib): Highlights of Prescribing Information","author":"US Food and Drug Administration","year":"2022"},{"key":"2025050812114049700_R15","article-title":"Drug Report: Xeljanz 5 mg Tablets (Tofacitinib Citrate)","author":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan","year":"2018"},{"key":"2025050812114049700_R16","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025050812114049700_R17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2025050812114049700_R18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025050812114049700_R19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025050812114049700_R20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cei\/uxac085","article-title":"Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response","volume":"210","author":"Valli","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2025050812114049700_R21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/cei.12234","article-title":"Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis","volume":"175","author":"Migita","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025050812114049700_R22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molimm.2022.04.003","article-title":"IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms","volume":"146","author":"Ngwa","year":"2022","journal-title":"Mol Immunol"},{"key":"2025050812114049700_R23","article-title":"Herpes zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025050812114049700_R24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025050812114049700_R25","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025050812114049700_R26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050812114049700_R27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2025050812114049700_R28","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025050812114049700_R29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"2025050812114049700_R30","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9614241","article-title":"Review of routine laboratory monitoring for patients with rheumatoid arthritis receiving biologic or nonbiologic DMARDs","volume":"2017","author":"Rigby","year":"2017","journal-title":"Int J Rheumatol"},{"key":"2025050812114049700_R31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025050812114049700_R32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025050812114049700_R33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"key":"2025050812114049700_R34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V86.1.23.bloodjournal86123","article-title":"Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets","volume":"86","author":"Miyakawa","year":"1995","journal-title":"Blood"},{"key":"2025050812114049700_R35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/09537104.2021.1934665","article-title":"Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function","volume":"33","author":"Parra-Izquierdo","year":"2022","journal-title":"Platelets"},{"key":"2025050812114049700_R36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025050812114049700_R37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"2025050812114049700_R38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848211054710","article-title":"Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies","volume":"14","author":"Lees","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025050812114049700_R39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cyto.2011.01.007","article-title":"IL-6 plays an essential role in neutrophilia under inflammation","volume":"54","author":"Hashizume","year":"2011","journal-title":"Cytokine"},{"key":"2025050812114049700_R40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41423-020-00608-1","article-title":"Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension","volume":"18","author":"Florentin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025050812114049700_R41","first-page":"160","article-title":"The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production","volume":"167","author":"Williams","year":"1992","journal-title":"Ciba Found Symp"},{"key":"2025050812114049700_R42","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1073\/pnas.84.24.9035","article-title":"Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors","volume":"84","author":"Ikebuchi","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025050812114049700_R43","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"2025050812114049700_R44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2174\/1871530323666221017153157","article-title":"Interleukin-6 blockers improve inflammation-induced lipid metabolism impairments but induce liver fibrosis in collagen-induced arthritis","volume":"23","author":"Denga","year":"2023","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2025050812114049700_R45","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond.)"},{"key":"2025050812114049700_R46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025050812114049700_R47","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae109\/61008672\/roae109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/3\/417\/61008672\/roae109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/3\/417\/61008672\/roae109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T16:12:00Z","timestamp":1746720720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/3\/417\/7919772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae109","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,10]]}}}